These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 15367532)

  • 1. Aldosterone blockade in cardiovascular disease.
    Struthers AD
    Heart; 2004 Oct; 90(10):1229-34. PubMed ID: 15367532
    [No Abstract]   [Full Text] [Related]  

  • 2. Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
    Struthers AD; MacDonald TM
    Cardiovasc Res; 2004 Mar; 61(4):663-70. PubMed ID: 14985063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of aldosterone antagonists in the cardiovascular diseases].
    Trzaska E; Gumułka W; Makulska-Nowak HE
    Kardiol Pol; 2009 Jun; 67(6):667-71. PubMed ID: 19618325
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cardiovascular action of aldosterone].
    Miyamori I; Kawai Y; Fan CY
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():40-5. PubMed ID: 16895168
    [No Abstract]   [Full Text] [Related]  

  • 5. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease.
    Epstein M
    Am J Med; 2006 Nov; 119(11):912-9. PubMed ID: 17071154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone and specific aldosterone receptor antagonists in hypertension and cardiovascular disease.
    Bravo EL
    Curr Hypertens Rep; 2003 Apr; 5(2):122-5. PubMed ID: 12642011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
    Rosano GMC; Tamargo J; Kjeldsen KP; Lainscak M; Agewall S; Anker SD; Ceconi C; Coats AJS; Drexel H; Filippatos G; Kaski JC; Lund L; Niessner A; Ponikowski P; Savarese G; Schmidt TA; Seferovic P; Wassmann S; Walther T; Lewis BS
    Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):180-188. PubMed ID: 29726985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.
    Waanders F; de Vries LV; van Goor H; Hillebrands JL; Laverman GD; Bakker SJ; Navis G
    Curr Vasc Pharmacol; 2011 Sep; 9(5):594-605. PubMed ID: 21529330
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mineralocorticoid receptor antagonists in chronic kidney disease - pros and cons].
    Jędras M; Filipowicz E
    Wiad Lek; 2017; 70(6 pt 2):1205-1208. PubMed ID: 29533915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldosterone as a determinant of cardiovascular and renal dysfunction.
    Epstein M
    J R Soc Med; 2001 Aug; 94(8):378-83. PubMed ID: 11461980
    [No Abstract]   [Full Text] [Related]  

  • 11. Hyperkalaemia in the age of aldosterone antagonism.
    Chapagain A; Ashman N
    QJM; 2012 Nov; 105(11):1049-57. PubMed ID: 22723454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular actions of aldosterone.
    Briet M; Schiffrin EL
    J Vasc Res; 2013; 50(2):89-99. PubMed ID: 23172373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Old and new drugs to block aldosterone and ameliorate cardiovascular disease].
    Fiebeler A; Luft FC
    Dtsch Med Wochenschr; 2004 Nov; 129(46):2491-6. PubMed ID: 15536584
    [No Abstract]   [Full Text] [Related]  

  • 14. Aldosterone: effects on the kidney and cardiovascular system.
    Briet M; Schiffrin EL
    Nat Rev Nephrol; 2010 May; 6(5):261-73. PubMed ID: 20234356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperkalemia and inhibitors of the renin-angiotensin-aldosterone system.
    Segal A
    N Engl J Med; 2004 Dec; 351(23):2450-1; author reply 2450-1. PubMed ID: 15575066
    [No Abstract]   [Full Text] [Related]  

  • 16. Aldosterone and end-organ damage.
    Marney AM; Brown NJ
    Clin Sci (Lond); 2007 Sep; 113(6):267-78. PubMed ID: 17683282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual blockade of the renin-angiotensin-aldosterone system: beyond the ACE inhibitor and angiotensin-II receptor blocker combination.
    Bomback AS; Toto R
    Am J Hypertens; 2009 Oct; 22(10):1032-40. PubMed ID: 19661925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldosterone: cardiovascular assault.
    Struthers AD
    Am Heart J; 2002 Nov; 144(5 Suppl):S2-7. PubMed ID: 12422134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Role of RAAS inhibitors for the treatment of heart failure].
    Murohara T
    Nihon Rinsho; 2012 Sep; 70(9):1577-81. PubMed ID: 23012806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectively targetting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors.
    Weinberg MS; Weinberg AJ; Zappe DH
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):217-33. PubMed ID: 11881029
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.